Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3164-3171

  Kurata, Takayasu ^a   Shimada, Yasuhiro ^a   Tamura, Tomohide ^a   Yamamoto, Noboru ^a   Hyodo, Ichinosuke ^a   Saeki, Toshiaki ^a   Takashima, Shigemitsu ^a   Fujiwara, Keiichi ^a   Wakasugi, Hideyuki ^a   Kashimura, Masaki ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL; RPR 109881A; TAXANE DERIVATIVE; TAXOID; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; URINARY EXCRETION;

EID: 0033863452     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3164     Document Type: Article

References (19)

1. Promotion of microtubule assembly in vitro by Taxol
2. Relationships between the structure of taxol analogues and their antimitotic activity
3. Microtuble changes and cytotoxicity in leukemic cell lines treated with taxol
4. Taxol: Mechanisms of action and resistance
5. Pharmacology of drugs that alter multidrug resistance in cancer
6. Studies with RP 56976 (Taxotere): A semisynthetic analog of Taxol
7. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers
8. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion
9. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion
10. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis
11. Pharmacology of the taxanes
12. Selective biotransformation of Taxol to 6-alpha-hydroxytaxol by human cytochrome P450 2C8
13. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver
14. A phase I and pharmacokinetics (PK) study of RPR 109881A given as 6-hour IV infusion in patients (pts) with advanced solid tumors
15. Phase I trial of RPR 109881A (RPR), a novel taxoid derivative, administered as a 24-hour continuous infusion
16. Phase I trial of the new taxoid RPR 109881A in a day 1 and 8 intravenous (IV) schedule every 3 weeks: An NCI Canada clinical trials group study
17. Pharmacokinetics of a new taxoid (RPR 109881A): Comparison of five different administration schedules